Association Between Remnant Cholesterol and Risk of Hyperuricemia: A Cross-Sectional Study

Abstract

Remnant cholesterol (RC) is closely related to metabolic diseases. Our study aims to explore the relationship between RC and hyperuricemia. This cross-sectional study included 14 568 adults aged 20 years or older from the National Health and Nutrition Examination Survey (NHANES) conducted between 2007 and 2018 in the United States. RC is calculated by subtracting high-density lipoprotein cholesterol (HDL-c) and low-density lipoprotein cholesterol (LDL-c) from total cholesterol (TC). Hyperuricemia is defined by serum uric acid (SUA) levels≥7 mg/dl in men and≥6 mg/dl in women. The independent association between RC and hyperuricemia was evaluated. As the quartile range of RC levels increases, the prevalence of hyperuricemia also rises (7.84% vs. 13.71% vs. 18.61% vs. 26.24%, p<0.001). After adjusting for confounding factors, the fourth quartile of RC was associated with an increased risk of hyperuricemia compared with the first quartile (OR=2.942, 95% CI 2.473–3.502, p<0.001). Receiver Operating Characteristic (ROC) analysis shows that RC outperforms other single lipid indices in hyperuricemia. Further Restricted Cubic Splines (RCS) analysis suggests a nonlinear relationship between RC levels and hyperuricemia. Elevated RC levels were found to be linked to hyperuricemia. Further studies on RC hold promise for both preventing and addressing hyperuricemia.

Keywords

remnant cholesterol - hyperuricemia - NHANES - population-based study - nonlinear relationship

Publication History

Received: 06 March 2024

Accepted after revision: 03 April 2024

Accepted Manuscript online:
03 April 2024

Article published online:
02 May 2024

• References

• 1 Maiuolo J, Oppedisano F, Gratteri S. et al. Regulation of uric acid metabolism and excretion. Int J Cardiol 2016; 213: 8-14
• 2 Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 2020; 16: 380-390
• 3 Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheumatology (Oxford) 2013; 52: 34-44
• 4 Crawley WT, Jungels CG, Stenmark KR. et al. U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia. Redox Biol 2022; 51: 102271
• 5 Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med 2017; 15: 123
• 6 Oral A, Sahin T, Turker F. et al. Relationship between serum uric acid levels and nonalcoholic fatty liver disease in non-obese patients. Medicina (Kaunas) 2019; 55: 600
• 7 Ahn JK. Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean. J Rheum Dis 2023; 30: 88-98
• 8 Stürzebecher PE, Katzmann JL, Laufs U. What is 'remnant cholesterol'?. Eur Heart J 2023; 44: 1446-1448
• 9 Wadström BN, Wulff AB, Pedersen KM. et al. Remnant cholesterol in the era of intensive lipid-lowering therapies. Eur Heart J 2023; 44: 3483
• 10 Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188
• 11 Quispe R, Martin SS, Michos ED. et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur Heart J 2021; 42: 4324-4332
• 12 Hu X, Liu Q, Guo X. et al. The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus. Cardiovasc Diabetol 2022; 21: 117
• 13 Chen J, Su Y, Su X. et al. Remnant cholesterol has a non-linear association with non-alcoholic fatty liver disease. Diabetes Res Clin Pract 2023; 201: 110733
• 14 Zou Y, Kuang M, Zhong Y. et al. Remnant cholesterol can identify individuals at higher risk of metabolic syndrome in the general population. Sci Rep 2023; 13: 5957
• 15 Zou Y, Lan J, Zhong Y. et al. Association of remnant cholesterol with nonalcoholic fatty liver disease: a general population-based study. Lipids Health Dis 2021; 20: 139
• 16 Fang Y, Mei W, Wang C. et al. Dyslipidemia and hyperuricemia: a cross-sectional study of residents in Wuhu, China. BMC Endocr Disord 2024; 24: 2
• 17 Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821
• 18 Levey AS, Stevens LA, Schmid CH. et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
• 19 Cheng J, Sun J, Yao K. et al. A variable selection method based on mutual information and variance inflation factor. Spectrochim Acta A Mol Biomol Spectrosc 2022; 268: 120652
• 20 Sascău R, Clement A, Radu R. et al. Triglyceride-rich lipoproteins and their remnants as silent promoters of atherosclerotic cardiovascular disease and other metabolic disorders: a review. Nutrients 2021; 13: 1774
• 21 Jørgensen AB, Frikke-Schmidt R, West AS. et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013; 34: 1826-1833
• 22 Sandesara PB, Virani SS, Fazio S. et al. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev 2019; 40: 537-557
• 23 Huang H, Xie J, Zeng Y. et al. Remnant cholesterol independently Ppredicts the development of nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2023; 108: 2907-2915
• 24 Szili-Torok T, Sokooti S, Osté MCJ. et al. Remnant lipoprotein cholesterol is associated with incident new onset diabetes after transplantation (NODAT) in renal transplant recipients: results of the TransplantLines Biobank and cohort Studies. Cardiovasc Diabetol 2022; 21: 41
• 25 Pillinger MH, Bangalore S, Klein AB. et al. Cardiovascular disease and gout: real-world experience evaluating patient characteristics, treatment patterns, and health care utilization. J Manag Care Spec Pharm 2017; 23: 677-683
• 26 Hu X, Rong S, Wang Q. et al. Association between plasma uric acid and insulin resistance in type 2 diabetes: a Mendelian randomization analysis. Diabetes Res Clin Pract 2021; 171: 108542
• 27 Ohnishi H, Saitoh S, Takagi S. et al. Relationship between insulin-resistance and remnant-like particle cholesterol. Atherosclerosis 2002; 164: 167-170
• 28 Shalaurova I, Connelly MA, Garvey WT. et al. Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance. Metab Syndr Relat Disord 2014; 12: 422-429
• 29 Garvey WT, Kwon S, Zheng D. et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52: 453-462
• 30 Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733-749
• 31 Haas ME, Attie AD, Biddinger SB. The regulation of ApoB metabolism by insulin. Trends Endocrinol Metab 2013; 24: 391-397
• 32 Song Y, Liu J, Zhao K. et al. Cholesterol-induced toxicity: an integrated view of the role of cholesterol in multiple diseases. Cell Metab 2021; 33: 1911-1925
• 33 Conen D, Wietlisbach V, Bovet P. et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health 2004; 4: 9
• 34 Deedwania PC, Stone PH, Fayyad RS. et al. Improvement in renal function and reduction in serum uric acid with intensive statin therapy in older patients: a post hoc analysis of the SAGE trial. Drugs Aging 2015; 32: 1055-1065
• 35 Akbari A, Razmi M, Rafiee M. et al The effect of statin therapy on serum uric acid levels: a systematic review and meta-analysis. Curr Med Chem 2023;
• 36 Zhou S, Wu L, Si H. et al. Longitudinal association between uric acid and incident sarcopenia. Nutrients 2023; 15: 3097
• 37 Tarantino G, Sinatti G, Citro V. et al. Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression?. Intern Emerg Med 2023; 18: 1887-1895
• 38 Bi B, Dong X, Yan M. et al. Dyslipidemia is associated with sarcopenia of the elderly: a meta-analysis. BMC Geriatr 2024; 24: 181